Mycophenolate mofetil versus cyclophosphamide, in combination with prednisolone for lupus nephritis induction treatment: Findings from a prospective observational study
DOI:
https://doi.org/10.71152/ajms.v16i7.4589Keywords:
Lupus nephritis; Mycophenolate mofetil; Remission induction; Cyclophosphamide; Side effectsAbstract
Background: Lupus nephritis (LN) is a severe complication of systemic lupus erythematosus. Intravenous cyclophosphamide (CYC) is the standard induction therapy for proliferative LN, but it is associated with serious adverse effects such as sterility and bone marrow suppression. Mycophenolate mofetil (MMF) has emerged as a promising alternative, offering better renal outcomes and preserving fertility in women of childbearing age.
Aims and Objectives: To compare the treatment outcomes and safety of MMF plus prednisolone versus CYC plus prednisolone in the induction treatment of LN.
Materials and Methods: Patients with Class 3 and 4 LN who received either oral MMF (2 g/day) or CYC (0.75–1 g/m2) were included in the study. Remission rates and adverse events were measured as treatment outcomes.
Results: The study found 81% remission in the MMF group compared to 76.4% in the CYC group (not statistically significant). Adverse effects in the MMF group included headache (52.4%), bone marrow toxicity (47.6%), back pain (42.9%), and gastrointestinal side effects (42.8%). The CYC group had higher rates of bone marrow toxicity (57.1%), respiratory infections (33.3%), and mucocutaneous infections (57.1%). Notably, alopecia (4.8% vs. 52.4%, P=0.001) and amenorrhea (4.8% vs. 28.6%, P=0.04) were significantly lower in the MMF group.
Conclusion: The MMF-steroid regimen is highly effective for inducing remission in proliferative LN and offers a more favorable safety profile than the CYC-steroid regimen.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Asian Journal of Medical Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Authors who publish with this journal agree to the following terms:
- The journal holds copyright and publishes the work under a Creative Commons CC-BY-NC license that permits use, distribution and reprduction in any medium, provided the original work is properly cited and is not used for commercial purposes. The journal should be recognised as the original publisher of this work.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
